Roche to Buy RNAi and Gene Therapy Company Mirus Bio for $125M | GenomeWeb
NEW YORK (GenomeWeb News) – Roche said today that it will buy RNAi technologies company Mirus Bio Corporation for $125 million.
 
Roche plans to divest Mirus’ transfection reagents into a stand-alone business called Mirus Bio LLC, and it expects to offer employees of the Madison, Wis.-based company a transition into respective business units. The Swiss firm intends to retain an RNAi research site at the facilities in Madison.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.